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SUMMARY
Methylmercury (MeHg) is an environmental pollutant that is highly toxic to the cen-
tral nervous system. As its effects on male reproductive system are poorly understood,
this study was carried out to analyse the effects of MeHg on the rat prostate. To evalu-
ate the MeHg toxicity on ventral prostate, three groups of adult male Wistar rats
received oral doses of 0.5, 1.0 and 3.0 mg/kg MeHg, respectively, on a daily basis for
14 days. A fourth group was used as a control. The prostate weight was decreased in
rats treated orally with 0.5 mg/kg MeHg compared to controls. Also, Hg concentra-
tion increased significantly in the prostate after treatments. There were reductions in
serum testosterone levels and androgen receptor immunoreactivity in animals receiving
3.0 mg MeHg/kg. The stereological data showed changes in the prostatic epithelial,
stromal and luminal compartments which varied according to the different doses. His-
topathological alterations, such as chronic inflammation, stratified epithelial hyper-
plasia and epithelial inflammatory reactive atypia, were observed in the 0.5 mg/kg
MeHg-treated group. Epithelial atrophy was observed in the 3.0 mg/kg MeHg-treated
group. In conclusion, the MeHg affects prostatic homoeostasis resulting in histopatho-
logical changes that may be relevant in the pathogenesis of prostatic disease.
Keywords
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Mercury is a widespread environmental contaminant that
enters the environment from a variety of industrial processes
as well as from the earth’s crust (Nriagu 1979). Mercury
(Hg) is converted into methylmercury (MeHg) by aquatic
bacteria and is passed along the food chain where it accu-
mulates in fish and marine mammals.
Serious poisoning episodes, including those in Minamata
(Japan) and Iraq during the 1950s and 1970s, led to acute
MeHg intoxication, manifesting as severe nervous system
disturbances in thousands of local inhabitants (Franco et al.
2009).
MeHG is found mostly as a complex with free cysteine
and with proteins and peptides containing that amino acid.
The methylmercuric-cysteinyl complex is recognized by
amino acid transporting proteins in the body as methionine,
another essential amino acid (Kerper et al. 1992). Because
of this mimicry, it is transported freely throughout the body
including across the blood–brain barrier and across the
placenta, where it is absorbed by the developing foetus. Also
for this reason as well as its strong binding to proteins,
MeHg is not readily eliminated. The MeHg toxic effects are
probably mediated via interaction with many of the vital
enzymes involved in antioxidant regulation (Branco et al.
2012).
MeHg poisoning can result in several pathological condi-
tions, including microcephaly, mental retardation, cerebral
palsy, seizures, ataxia, anaemia, behavioural disturbances
and reproductive dysfunction (Myers & Davidson 1998).
Growing evidences have indicated that exposure to MeHg
can decrease male fertility (Khera 1973; Rao 1989; Rao &
Gangadharan 2008). MeHg can pass through the blood–
testis barrier acting directly on developing germ cells to alter
spermatogenesis (Lee & Dixon 1975; Homma-Takeda et al.
2001). In rats, daily injections of MeHg can decrease both
testicular and epididymal weight leading to increased cellu-
lar atrophy (Burton & Meikle 1980; Sun & Lin 1992) and
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germ cell apoptosis (Homma-Takeda et al. 2001). Previous
studies have emphasized that the exposure to MeHg
decrease testosterone levels (Vachhrajani & Chowdhry
1990; Vachhrajani et al. 1992; Homma-Takeda et al. 2001;
McVey et al. 2008). In addition, our recent study showed
that MeHg reduced serum testosterone levels in a dose-
dependent manner (Fossato da Silva et al. 2011), indicating
this metal as a potential endocrine disruptor (ED).
The prostate is an accessory gland, androgen dependent, of
the male urogenital system that contributes to the production
of seminal fluid components and promotes the maintenance
of ionic gradient and appropriate pH (Untergasser et al.
2005). At present, there is considerable clinical-pathological
interest in the prostate and its pathophysiology because pros-
tate cancer is now the most frequently diagnosed cancer
among men and the second leading cause of male cancer
deaths in the United States (Potosky et al. 1995; Parker et al.
1996). Additionally, the pathogenesis of prostate cancer
reflects both hereditary and environmental conditions.
In rodents several aspects of prostatic changes related to
chronic inflammation have been investigated. It appears that
chemical trauma, dietary factors, steroid hormones or com-
binations of different environmental factors are all involved
(De Marzo et al. 2007). Therefore, environmental factors
act as EDs that can contribute to the development of pros-
tatic diseases.
As the prostate is involved in several pathophysiological
processes and as its functions may be compromised during
MgHg exposure because of hormonal disturbances, the aim
of this study was to evaluate the effects of subacute exposure
to different doses of MeHg on the rat ventral prostate, focus-
ing on histopathological and immunohistochemical parame-
ters.
Material and methods
Animals
Adult male Wistar rats (n = 60), 80 days of age, (300–350 g)
were used for the study. Animals were obtained from Central
Biotherium of the UNESP – Univ Estadual Paulista and
housed in polypropylene cages (43 cm 9 30 cm 9 15 cm)
with laboratory-grade pine shavings as bedding. Rats were
maintained under controlled temperature (23 ± 1°C) and
lighting conditions (12:12-h photoperiod). Balanced rat chow
(Purina®) and filtered tap water were provided ad libitum.
Animals were allowed to adapt for at least 1 week before the
beginning of the experiment. The experimental protocol fol-
lowed the Ethical Principles in Animal Research of the Brazil
College of Animal Experimentation and was approved by the
Institute of Biosciences/UNESP Ethics Committee for Animal
Experimentation (Protocol n°: 05/08).
Experimental design
Rats were divided into four groups (n = 15): Control, 0.5,
1.0 or 3.0 mg/kg body weight/day MeHg orally (by gavage)
administered during 14 consecutive days (Fossato da Silva
et al. 2011). The doses used in our study are common in
reproductive toxicity induced by MeHg (McVey et al. 2008)
and in other experimental studies (Robinson et al. 2010;
Tonk et al. 2010). MeHg commercial solution (1 g/l) was pur-
chased from Merck® (Merck KGaA, Darmstadt, Germany),
dissolved in methanol (CH3OH) (Sigma Aldrich
®, St. Louis,
MO, USA) and Milli-Q water (Millipore®, Billerica, MA,
USA). Control group received distilled water by gavage.
Ventral prostates of ten rats per group were collected,
weighed and their fragments processed for histopathological
and morphometric-stereological analysis, and both for
androgen receptor (AR) expression and for expression of an
antigen associated with cell proliferation, Ki67, by immuno-
histochemistry (IHC). Prostate fragments were removed
from the other five rats per group to quantify Hg by ICP-
MS (Fossato da Silva et al. 2011).
Body weight and organ weights
On the 14th day after the MeHg exposure, all rats were
weighed and anaesthetized with CO2 followed by decapita-
tion. After decapitation, the ventral prostates were removed
(n = 10/group) and their weights (absolute and relative)
were determined.
Determination of Mercury (Hg) level
Prior to sample collection, plastic tips and bottles (Nalgen)
used in the procedure were cleaned by soaking in 10% (v/v)
nitric acid (HNO3) for 24 h and rinsing five times in Milli-
Q water, then dried in a class containing 100 laminar flow
hood to avoid contamination. Analyses for Hg were carried
out using a quadrupole inductively coupled plasma mass
spectrometer (ICP-MS ELAN DRCII, PerkinElmer, SCIEX,
Norwalk, CT, USA). The sample introduction system was com-
posed of a quartz cyclonic spray chamber and a Meinhard®
nebulizer connected by Tygon® tubes to the ICP-MS peristaltic
pump (set at 20 rpm). Other instrumental settings and opera-
tive conditions are reported in Fossato da Silva et al. (2011).
Hg analysis in ventral prostate was carried out according
to Batista et al. (2009) by weighing approximately 75 mg of
each tissue into conical tubes (15 ml). Then 1 ml of 50%
(v/v) tetramethylammonium hydroxide (TMAH) solution
was added to the samples, which were incubated at room
temperature for 12 h and the volume increased up to 10 ml
with a solution containing 0.5% (v/v) HNO3, 0.01% (v/v)
Triton® X-100. Analytical calibration standards were pre-
pared daily over the range of 0–20 lg/l in diluents contain-
ing 5% (v/v) TMAH, 0.5% (v/v) HNO3 and 0.01% (v/v)
Triton® X-100.
Quality control of the results
Quality control of prostate Hg levels was acquired by the
analysis of Certified Reference Materials (CRMs) purchased
from National Research Council Canada (NRCC) (DOLT-3,
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DORM-3 and TORT-2). Recovery ratios of Hg in all CRMs
were always in the range of 95–105%.
Histopathological analysis
The ventral prostate (n = 10/group) was removed, and frag-
ments selected from the distal part were fixed by immersion
in buffered formalin phosphate-buffered saline (PBS) for
24 h. Fixed tissue samples were dehydrated in a graded eth-
anol series and embedded in glycol methacrylate resin (Leica
historesin embedding kit Image-ProPlus, Media Cybernetics,
Nussloch, Germany). Histological sections (3 lm) were sub-
jected to haematoxylin–eosin (H&E) staining for general
studies. Histopathological and stereological analyses were
carried out on Leica and Olympus photomicroscopes, and the
microscopic fields were digitized using the software Image-
Pro®Plus version 4.5 forWindowsTM Bethesda,MD, USA.
Morphometric-stereological analysis
Resin embedded sections were stained by H&E and quan-
titated by means of an imaging analysis system (Image-
Pro®Plus version 4.5 for WindowsTM software). For this
purpose 100 histological fields randomly chosen from the
distal part of the ventral prostate were captured and anal-
ysed via the stereological method with all histological
fragments equally evaluated (n = 20/animal). Stereological
analyses were obtained by Weibel’s multipurpose graticu-
late, with 120 points and 60 test lines (Weibel 1963) to com-
pare the relative proportions among the prostatic components
(epithelium, stroma and lumen) in the experimental groups.
Immunohistochemistry
Androgen receptor (AR) (1:100/SC-816, rabbit polyclonal
IgG, epitope mapping at the N-terminus of AR; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and Ki67
(1:100/ab16667; Ki67 – Proliferation Marker, abcam®,
Cambridge, MA, USA) primary antibodies were used for
IHC assay. The IHC reaction was performed using the
avidin–biotin complex (ABC) kit (Santa Cruz Biotechnol-
ogy) for AR and the Mach4TM BioCare Polymer kit
(Biocare Medical, concord, CA, USA) for Ki67. For IHC,
the ventral prostates were fixed in formaldehyde buffered
PBS (10%), dehydrated in alcohol and embedded in
paraplast. The sections (5 lm) were dewaxed and then re-
hydrated in graded alcohol and distilled water. Antigen
retrieval was conducted in sodium citrate buffer
(pH = 6.0) at high temperature (~100 °C) by steam cooker
during 45–50 min. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide in methanol for
30 min, followed by a quick rinse in distilled water and
PBS and then incubated in 1% bovine serum in PBS for
1 h or Background Sniper (Biocare®) for 15 min, to block
non-specific binding. Sections were incubated with the pri-
mary antibody at 4 °C overnight. The slides were then
incubated with biotinylated secondary antibody at 37 °C
followed by peroxidase-conjugated avidin–biotin complexes
and chromogen diaminobenzidine (DAB) and HRP-Poly-
mer (Biocare®). The sections were finally counterstained
with Harris’s haematoxylin. As a negative control, the pri-
mary antibody was replaced with the corresponding nor-
mal isotype serum.
AR semi-quantitative analysis
Five histological sections were analysed per group, and 10
AR-positive nuclei were randomly selected by section
(50 nuclei/group). The images of the selected nuclei were
cut in a regular and constant rectangular form (always in
central part of the nucleus, in view of the homogeneity of
nuclear staining/reactivity for AR) and those ‘rectangles’ were
submitted to optical densitometry analyser using SCION
Image forWindows Software® (Fossato da Silva et al. 2011).
Antigen for cell proliferation (Ki67)
The number of epithelial cells which express Ki67 was
counted in 50 fields/group, at 4009 magnification from five
different prostate fragments (10 fields/each fragment) and
expressed as percentage of the total cells counted. All image
acquisition and quantitative measurements were carried out
in a blinded fashion to both animal identity and experimen-
tal condition.
Statistical analysis
All results from the MeHg-treated groups vs. control group
were statistically compared by the non-parametric Kruskal–
Wallis test, complemented by the Dunns test in the GraphPad
Prism® software. Values are expressed as mean ± SEM and
medians (Q1–Q3). Statistical significance was set at P < 0.05.
Results
The absolute and relative weight of the ventral prostate was
seen to decrease after 0.5 mg/kg MeHg administration com-
pared to control group (Table 1). The level of Hg increased
significantly in the prostate of all treated groups, showing a
direct relationship between the administered dose and Hg
concentration in the tissue. Accordingly, the 3.0 mg/kg
MeHg-treated animals contained higher levels of prostatic
Hg than the other groups (Table 1). The body weight did
not differ among the groups (data not shown).
Inflammatory foci were observed in 60% of the animals
treated with 0.5 mg/kg MeHg and consisted mainly of
mononuclear cells (predominantly small lymphocytes) with
an increase in blood vessels in the stroma (Figure 1c), as
well as stratified focal hyperplasia (Figure 1d).
In the 1.0 mg/kg MeHg-treated group, the appearance of
periacinar connective tissue was identified adjacent to the epi-
thelium, causing epithelial folds (Figures 1e–f). In 3.0 mg/kg
MeHg group, the glandular epithelium presented a predomi-
nantly low cubic and squamous aspect (Figures 1g–h). The
International Journal of Experimental Pathology, 2012, 93, 354–360
356 D. A. F. da Silva et al.
nuclear-to-cytoplasmic ratio was apparently higher in these
animals than in others. The changes in the epithelium and the
accumulation of secretion in the lumen could have contributed
to the dilation of glandular acini, increasing the glandular
lumen in this experimental group (Figure 1g; Table 2).
Stereological data showed an increased epithelial compo-
nent in the 0.5 and 1.0 mg/kg MeHg-treated groups, while
the 3.0 mg/kg MeHg and control groups were unchanged.
The stromal component decreased in the 1.0 and 3.0 mg/kg
MeHg groups in relation to the control and 0.5 mg/kg
MeHg groups. Also, the luminal component was increased
after 3.0 mg/kg MeHg compared to other groups (Table 2).
AR immunoreactivity was similar between control, 0.5 and
1.0 mg/kg MeHg groups (Figure 2a–c, e). However, after
3.0 mg/kg MeHg, the AR labelling showed lower intensity in
the epithelial cells (Figure 2d–e). The proliferation index (as
judged by numbers of Ki67-positive cells showed a significant
increase after treatment only in the 0.5 mg/kg MeHg group
compared to control and other groups (control: median =
0.55%; 0.5 mg/kg MeHg: median = 1.35%*; 1.0 mg/kg MeHg:
median = 0.6%; 3.0 mg/kgMeHg: median = 0.5%; *P  0.05).
Discussion
Although several studies have reported the toxicity of MeHg
in some bodily systems, such as nervous system (Sanfeliu
et al. 2003; Crespo-Lo´pez et al. 2005) and immune system
(Ha¨ggqvist et al. 2005), there are few reports about the
Table 1 Absolute and relative prostate weight and prostate mercury levels in control group and methylmercury (MeHg)-treated
groups at doses 0.5, 1.0 and 3.0 mg/kg after 14 days of MeHg treatment
Parameters Control (n = 9) 0.5 mg/kg (n = 10) 1.0 mg/kg (n = 10) 3.0 mg/kg (n = 10)
Prostate (mg) 510.79 ± 22.41 421.54 ± 19.54* 523.85 ± 14.83 486. 65 ± 29.51
Prostate (mg/100 g) 126.25 ± 7.76 103.73 ± 4.15* 120.68 ± 3.91 126.90 ± 6.04
Mercury (lg/ml) 0.01 ± 0.01 0.29 ± 0.02 0.71 ± 0.04 2.06 ± 0.03**
Values are expressed as mean ± SEM.
*P < 0.05.
**P < 0.01.
Non-parametric Kruskall–Wallis test, complemented by Dunns test.
(a)
(b)
(c)
(d)
(e)
(f) (g)
(h)
Figure 1 Haematoxylin–eosin (H&E) staining. (a–b) Histological sections from Control Group ventral prostate; a: general aspect of
the distal segment of the gland; b: detail of the epithelium. (c–d) Histological sections from 0.5 mg/kg methylmercury (MeHg)-
treated group; c, general aspect of the distal segment of the gland. Inflammatory focus (inf/arrow) occupying the stroma (st) of the
gland; presence of large veins (v); d, detail showing an epithelial hyperplasia (arrow). (e–f) Histological sections from 1.0 mg/kg
MeHg-treated group: e, general aspect of the gland showing papillary hyperplasia with folds (arrow) in the supporting vascularized
connective tissue; (f) detail of the epithelial fold. The arrow indicates the connective tissue inserted in an epithelial fold. (g–h)
Histological sections from 3.0 mg/kg MeHg-treated group: g: prostatic acini at low magnification. There is evidence of an increase in
the luminal compartment; h, Detail showing the squamous dysplasia of epithelium. The arrow points to the flattened cells. General
abbreviations: epithelium (ep); stroma (st); lumen (lu); inflammatory focus (inf); blood vessel (v).
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MeHg effects on the male reproductive system (Homma-
Takeda et al. 2001; Fossato da Silva et al. 2011). Fossato
da Silva et al. (2011) using the same experimental protocol
showed that testosterone levels decrease after a dose of
3.0 mg/kg MeHg. Therefore, previous results obtained by
Fossato da Silva and collaborators (Fossato da Silva et al.
2011) will be considered for the discussion.
It is known that environmental and dietary factors are
probably responsible for causing significant changes in the
concentrations and metabolism of sex steroid hormones,
which contribute to the development of prostatic lesions and
diseases (Hsing & Devesa 2001) as they epidemiologically
manifest in regions of high exposure to EDs.
The prostate weight decreased after 0.5 mg/kg MeHg and
this seems to be associated with a local effect of MeHg,
since other markers, such as systemic hormone levels and
body weight were not altered in this group. Another hypoth-
esis could be that the accumulation of MeHg, which in low
doses can act as an anti-androgenic agent by blocking
enzymes, such as aromatase, which converts testosterone
into dihydrotestosterone.
The increase in MeHg in the tissue may be related to
increased oxidative stress (Crespo-Lo´pez et al. 2009) and
consequently to the adaptive rearrangement of the gland
because of local stress. Increases in the epithelial compart-
ment of the 0.5 mg/kg MeHg group reflect the prostatic
Table 2 Weibel’s stereology analyses of control group and methylmercury (MeHg)-treated groups at doses of 0.5, 1.0 and 3.0 mg/kg
after 14 days of MeHg treatment; n = 50 fields/group
Relative Proportion (%) Control 0.5 mg/kg 1.0 mg/kg 3.0 mg/kg
Epithelium 19.94 (17.26–23.95) 27.97 (23.51–33.48)*** 26.78 (23.36–32.14)*** 16.07 (11.90–21.42)
Stroma 18.75 (11.45–23.95) 16.37 (12.94–25.14) 10.12 (8.18–17.70)* 8.33 (5.95–11–45)***
Lumen 59.82(51.48–66.07) 54.76 (44.49–59.67) 62.50 (49.85–66.96) 75.00 (66.96–79.46)***
Values are expressed as median (Q1–Q3).
*P < 0.05.
***P < 0.001.
Non-parametric Kruskall–Wallis test, complemented by Dunns test.
(a) (b)
(c) (d)
(e)
Figure 2 Histological sections submitted
to androgen receptor (AR) immunohisto-
chemistry. (a) Control Group; (b) (0.5
mg/kg methylmercury (MeHg)-treated
group); (c) (1.0 mg/kg MeHg-treated
group); (d) (3.0 mg/kgMeHg-treated group):
note that there is marked epithe-
lial atrophy with more compact nuclei
and a great reduction in cytoplasmic
volume. Brown stain signifies AR-
positive reactivity. The arrows indicate
AR-positive cells. General abbreviations:
epithelium (ep); stroma (st); lumen (lu);
inflammatory focus (inf). (e) Semi-
quantitative analysis (IOD integrated
optical density) of the nuclear epithelial
cells (n = 50 nuclei/group) AR immuno-
reactivity from prostate following MeHg
treatment at doses of 0.5, 1.0 and
3.0 mg/kg for 14 days. Values are
expressed as means ± SEM. Different
‘letters’ indicate significant difference
among the groups (P  0.05).
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tissue adaptation to Hg accumulation (Crespo-Lo´pez et al.
2009). A third aspect to be considered is the reactive induc-
tion produced by stromal inflammatory cells as small lym-
phocytes associated with epithelial proliferation (Shappell
et al. 2004).
In the 1.0 mg/kg MeHg-treated group, an increase in the
epithelial and a decrease in the stromal compartments were
observed. These features may be associated with the disrup-
tion produced by mercury in the tissue and by the decrease
in the testosterone availability. This aspect could be impor-
tant in trying to justify the folding of the epithelial layer
and the appearance of adjacent connective tissue, which can
be observed in the experiments followed by castration
(Vilamaior et al. 2000; Scarano et al. 2008).
A significant increase in the luminal component and a
reduction in other components were observed in the 3.0 mg/
kg MeHg group. These modifications are supported by epi-
thelial atrophy and dilation of the glandular acini, which
seems to be primarily because of a decrease in testosterone
levels (Crespo-Lo´pez et al. 2009). Furthermore, it is well-
known that MeHg adversely alters male steroidogenesis,
(Vachhrajani & Chowdhry 1990; McVey et al. 2008).
Results from chemical and surgical castration using experi-
mental models revealed similar glandular atrophy in the
prostate (Vilamaior et al. 2000; Oliveira et al. 2007;
Scarano et al. 2008).
Tissue changes such as reactive epithelial atypia and strat-
ified hyperplasia have been observed in the 0.5 MeHg-
treated group, which presented frequent chronic inflamma-
tion. The same histopathological feature was found in a
study using low doses of di-n-butyl-phthalate (DBP) during
pregnancy and lactation (Scarano et al. 2009) and after xe-
noestrogen treatments such as diethylstilbestrol (Timms
et al. 2005). In rodents, the aspects which could be related
to the chronic inflammation include chemical trauma, die-
tary factors, steroid hormones or combinations of different
environmental factors (De Marzo et al. 2007). It is impor-
tant because epidemiological, histopathological and molecu-
lar pathological studies in humans have also demonstrated
evidence that inflammation is involved in the pathogenesis
of prostate cancer (De Marzo et al. 2004, 2007; Palapattu
et al. 2005).
Our results demonstrate that for each MeHg treatment,
there has been an association with a typical histopathologi-
cal response pattern. Moreover MeHg interfered with the
homoeostasis of the gland; however, in the 0.5 mg/kg MeHg
treatment, there was a compensatory effect. Conversely, in
the 3.0 mg/kg MeHg treatment group, there was a decrease
in glandular activity, probably due to the endocrine imbal-
ance caused by the decrease in testosterone. The lowest dose
was seen to cause a slight imbalance that was reflected by
an adaptive response, creating focal changes such as an
inflammatory response and an increase in epithelial cell vol-
ume and proliferation. Curiously, this pattern of biological
response has been reported in studies using anti-androgens
such as Vinclozolin (Cowin et al. 2008), di-n-butyl-
phthalate (Scarano et al. 2009), and after oestrogen diethyl-
stilbestrol (DES) treatments (Timms et al. 2005). High doses
of DES during pregnancy may inhibit the development of
prostatic ducts; however, low doses can stimulate the prolif-
eration and prostate development, as already evidenced in
foetuses exposed to DES (Timms et al. 2005).
Part of the changes may be related to AR inactivation
caused by intracellular signalling proteins or by the bio-
availability of ligands (hormone or antagonist) (Feldman &
Feldman 2001). The presence of inflammatory cells was
related to a dose of 0.5 mg/kg MeHg group. Paracrine sig-
nals mediated by inflammatory factors can influence the dif-
ferentiation and adaptation of epithelial and stromal cells,
leading to dysplasia of the gland, reactive epithelial atypia
and stromal remodelling (Cowin et al. 2008; Scarano et al.
2009).
No changes were observed in the semi-quantitative pat-
tern of AR immunoreactivity in 0.5 and 1.0 MeHg-treated
groups as compared to the control group. However, there
was a reduction of AR immunoreactivity in the 3.0 MeHg-
treated group. This fact may be related to the reduced bio-
availability of the agonist (testosterone) and suggests a
reduction of AR activation and migration to nucleus,
decreasing the glandular activity, which could be directly
related to epithelial atrophy (Feldman & Feldman 2001).
The histopathology of the ventral prostate demonstrated
different responses pattern according to the MeHg dosage.
Also, there were tissue alterations in all treatments, suggest-
ing that MeHg, directly or indirectly, affects the prostatic
microenvironment homoeostasis.
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